Exhibit 99.1
| |
|
|
|
|
|
|
|
|
IMMEDIATE RELEASE
|
|
July 29, 2008
|
|
|
CONTACTS:
|
|
|
|
|
|
|
Brent Larson,
|
|
Tim Ryan,
|
|
|
Vice President / CFO
|
|
The Trout Group
|
|
|
614 822.2330
|
|
646.378.2924 |
|
|
NEOPROBE INCREASES BOARD OF DIRECTORS
Names Business Executive Gordon A. Troup to Board of Directors
DUBLIN, OHIO — July 29, 2008 — Neoprobe Corporation (OTCBB: NEOP), a diversified developer of
innovative oncology and cardiovascular surgical and diagnostic products, announced today that
Gordon A. Troup has been appointed to Neoprobe Corporation’s Board of Directors.
Mr. Troup recently retired as President of Cardinal Health’s Nuclear Pharmacy Services (NPS). Mr.
Troup spent 17 years with Cardinal Health, Inc. including five years as President of NPS and four
years as Group President of Pharmaceutical Distribution and Specialty Distribution Services. At NPS
Mr. Troup helped develop the largest radiopharmacy network in the United States with over 165
locations and 4,000 employees. Mr. Troup has also been active in numerous professional and
community organizations in the Columbus area and nationally.
Mr. Troup commented on his appointment to the Neoprobe Board of Directors, “I am excited to join
the Board at Neoprobe because of the great potential the Company has in helping to improve the
treatment and care of patients with cancer. Neoprobe has made great strides in the recent past and
I look forward to assisting in guiding the company in the coming years as the company prepares for
the commercial launch of Lymphoseek® and the development of additional products
including its RIGS® technology.”
David Bupp, Neoprobe’s President & CEO, said, “Neoprobe is very pleased to have someone of Gordon’s
business experience and stature join our Board, as we are making the transition to a biotechnology
company with both medical device and drug product offerings. Mr. Troup’s business and marketing
expertise will provide significant input as we prepare for the commercial launch of Lymphoseek and
as we consider development strategies for our portfolio of biomedical products. Mr. Troup has been
appointed to a Board term ending at the Annual Stockholders’ Meeting in 2009, when he is expected
to stand for election for another term ending in 2012.”
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by
meeting the critical intraoperative diagnostic information needs of physicians and therapeutic
treatment needs of patients. Neoprobe currently markets the Neoprobe GDS line of gamma detection
systems that are widely used by cancer surgeons and is commercializing the Quantix® line
of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition,
Neoprobe holds significant interests in the development of related biomedical systems and
radiopharmaceutical agents including Lymphoseek® and RIGScan® CR. Neoprobe’s
subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy
technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder
return by maximizing its strong position in gamma detection technologies and diversifying into new,
synergistic biomedical markets through continued investment and selective acquisitions.
www.neoprobe.com